Rajender Kumar Kamboj

This inventor holds 48 USPTO granted patents and 16 published patent applications, plus 5 CIPO patents and 18 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Lupin, Inc., Lupin Atlantis Holdings Sa. Active years: 2012-2026.

USPTO Granted Patents = 48 (Patent Applications = 16)

% Patents Active = 37.5

CIPO Patents = 5 (Patent Applications = 16)

EPO Patents = 18 (Patent Applications = 43)

Average Co-Inventor Count = 7.8

ph-index = 3

Forward Citations = 67(Granted Patents)

Location History:

Maharashtra, IN (2015 - 2019)
Pune, IN (2012 - 2024)

Company Filing History:

Lupin Atlantis Holdings Sa

patents

Years Active: 2012-2026

Loading Chart...

Areas of Expertise:

PRMT5 Inhibitors

CRAC Modulators

Calcium Sensing Receptor

Oxazoline Derivatives

Heterocyclic Compounds

Pyrrole Derivatives

Antiviral Compounds

Tricyclic Compounds

Chroman Compounds

Sulfonamide Compounds

MEK Inhibitors

Nicotinic Acetylcholine Receptor

48 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679849 - Macrocyclic compounds as STING agonists (2026-07-14),

2. 12673054 - Substituted nucleoside analogs as PRMT5 inhibitors (2026-07-07),

3. 12479858 - Macrocyclic compounds as sting agonists and methods and uses thereof (2025-11-25),

4. 12447152 - Pharmaceutical combination of PRMT5 inhibitors (2025-10-21),

5. 12435066 - Substituted tricyclic compounds (2025-10-07),

6. 12421204 - Process for preparing chroman compounds (2025-09-23),

7. 12391695 - PRMT5 inhibitors (2025-08-19),

8. 12344592 - Methods, processes and intermediates for preparing chroman compounds (2025-07-01),

9. 11952380 - Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors (2024-04-09),

10. 11459330 - Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors (2022-10-04),

11. 10292981 - Oxazoline and isoxazoline derivatives as CRAC modulators (2019-05-21),

12. 10239869 - Sulfonamide compounds as voltage-gated sodium channel modulators (2019-03-26),

13. 9987249 - Substituted chroman compounds as calcium sensing receptor modulators (2018-06-05),

14. 9969731 - Heterocyclyl compounds as MEK inhibitors (2018-05-15),

15. 9944639 - Quinolizinone derivatives as PI3K inhibitors (2018-04-17),

Title: Rajender Kumar Kamboj: Innovator in Pharmaceutical Patents

Introduction

Rajender Kumar Kamboj is a prominent inventor based in Pune, India, renowned for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 40 patents, his work has been pivotal in advancing medical treatments and addressing critical health issues.

Latest Patents

Among his latest innovations is the development of substituted bicyclic heterocyclic compounds as PRMT5 inhibitors. This invention encompasses compounds of a specific formula, their pharmaceutically acceptable salts, and the formulation of pharmaceutical compositions aimed at treating diseases, disorders, or conditions associated with the overexpression of the PRMT5 enzyme. The methods associated with this invention provide novel therapeutic approaches to combat various health challenges linked to PRMT5 overexpression.

Career Highlights

Rajender has had a remarkable career trajectory, having worked with esteemed organizations such as Lupin, Inc. and Lupin Atlantis Holdings Sa. His roles in these companies have equipped him with a wealth of experience in research and development, further driving innovation in the pharmaceutical sector.

Collaborations

Throughout his career, Rajender has collaborated with talented individuals, including Venkata Poornapragnacharyulu Palle and Neelima Sinha. These partnerships have likely fueled creative thinking and technical expertise, enriching the development of impactful medical solutions.

Conclusion

Rajender Kumar Kamboj exemplifies the spirit of innovation in the pharmaceutical industry. With his extensive patent portfolio and collaborative approach, he continues to make strides in developing novel therapies. His contributions not only highlight his expertise but also reflect the importance of research and collaboration in advancing healthcare solutions.